Literature DB >> 29209951

Relationship of left ventricular global longitudinal strain with cardiac autonomic denervation as assessed by 123I-mIBG scintigraphy in patients with heart failure with reduced ejection fraction submitted to cardiac resynchronization therapy : Assessment of cardiac autonomic denervation by GLS in patients with heart failure with reduced ejection fraction submitted to CRT.

Madalena Coutinho Cruz1, Ana Abreu2, Guilherme Portugal2, Helena Santa-Clara3, Pedro S Cunha2, Mario M Oliveira2, Vanessa Santos3, Luís Oliveira4, Pedro Rio2, Inês Rodrigues2, Luís A Morais2, Rui C Ferreira2, Miguel M Carmo2,5.   

Abstract

BACKGROUND: Heart failure (HF) is associated with cardiac autonomic denervation (AD), which can be non-invasively assessed by 123I-metaiodobenzylguanidine (123I-mIBG) scintigraphy and has prognostic implications. We aimed to study the relationship between myocardial contractility assessed by global longitudinal strain (GLS) and AD assessed by 123I-mIBG scintigraphy in advanced HF. METHODS/
RESULTS: BETTER-HF is a prospective randomized clinical trial including HF patients (pts) submitted to cardiac resynchronization therapy (CRT) who are submitted to a clinical, echocardiographic, and scintigraphic assessment before and 6 months after CRT. 81 pts were included. An echocardiographic response (absolute increase in left ventricular ejection fraction ≥ 10%) was observed in 73.7% of pts. A higher baseline late heart-to-mediastinum ratio (HMR) was associated with a better echocardiographic response. There was a significant association between late HMR and GLS at baseline and 6 months. At baseline, GLS had an AUC of 0.715 for discrimination for a late HMR < 1.6. A GLS cut-off of - 9% maximized the likelihood of correctly classifying a pt as having severe AD (HMR < 1.6).
CONCLUSION: Myocardial contractility as assessed by GLS is moderately correlated with AD as assessed by 123I-mIBG scintigraphy and has a good discrimination for the identification of severe cardiac denervation. GLS may allow for a more readily accessible estimation of the degree of AD in advanced HF pts.

Entities:  

Keywords:  Heart failure; diagnostic and prognostic application; left ventricular function; mIBG imaging

Mesh:

Substances:

Year:  2017        PMID: 29209951     DOI: 10.1007/s12350-017-1148-9

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  51 in total

Review 1.  Variation of heart-to-mediastinal ratio in (123)I-mIBG cardiac sympathetic imaging: its affecting factors and potential corrections.

Authors:  Wengen Chen; Qi Cao; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2011-04       Impact factor: 2.931

2.  Adverse consequences of high sympathetic nervous activity in the failing human heart.

Authors:  D M Kaye; J Lefkovits; G L Jennings; P Bergin; A Broughton; M D Esler
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

Review 3.  Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review.

Authors:  Hein J Verberne; Lizzy M Brewster; G Aernout Somsen; Berthe L F van Eck-Smit
Journal:  Eur Heart J       Date:  2008-03-17       Impact factor: 29.983

4.  Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy.

Authors:  Silvana A D'Orio Nishioka; Martino Martinelli Filho; Simone C Soares Brandão; Maria Clementina Giorgi; Marcelo L C Vieira; Roberto Costa; Wilson Mathias; José Cláudio Meneghetti
Journal:  J Nucl Cardiol       Date:  2007-10-18       Impact factor: 5.952

5.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

Review 6.  Epidemiology of heart failure.

Authors:  Véronique L Roger
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

7.  Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease.

Authors:  Mamoru Shibata; Yoko Morita; Toshihiko Shimizu; Kazushi Takahashi; Norihiro Suzuki
Journal:  J Neurol Sci       Date:  2008-10-05       Impact factor: 3.181

8.  Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function.

Authors:  Daigo Nagahara; Tomoaki Nakata; Akiyoshi Hashimoto; Takeru Wakabayashi; Michifumi Kyuma; Ryosuke Noda; Shinya Shimoshige; Kikuya Uno; Kazufumi Tsuchihashi; Kazuaki Shimamoto
Journal:  J Nucl Med       Date:  2008-01-16       Impact factor: 10.057

9.  A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.

Authors:  Tomoaki Nakata; Kenichi Nakajima; Shohei Yamashina; Takahisa Yamada; Mitsuru Momose; Shu Kasama; Toshiki Matsui; Shinro Matsuo; Mark I Travin; Arnold F Jacobson
Journal:  JACC Cardiovasc Imaging       Date:  2013-07

10.  Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation.

Authors:  Hein J Verberne; Jan B A Habraken; Berthe L F van Eck-Smit; Denis Agostini; Arnold F Jacobson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-06       Impact factor: 9.236

View more
  3 in total

1.  123I-meta-Iodobenzylguanidine Imaging in Patients with Cardiac Resynchronization Therapy: Results are Intriguing, but Unknowns Remain.

Authors:  Anisiia Doytchinova; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2018-08-01       Impact factor: 5.952

2.  Neuronal damage and abnormal contraction: Is the circle of synchronicity complete?

Authors:  Claudio Marcassa
Journal:  J Nucl Cardiol       Date:  2018-01-11       Impact factor: 5.952

3.  Prognostic effect and modulation of cardiac sympathetic function in heart failure patients treated with cardiac resynchronization therapy.

Authors:  Rita Ilhão Moreira; Ana Abreu; Guilherme Portugal; Luís Oliveira; Mário Oliveira; Inês Rodrigues; Madalena Coutinho Cruz; Pedro Silva Cunha; Vanessa Santos; Helena Santa Clara; Miguel Mota Carmo; Rui Cruz Ferreira
Journal:  J Nucl Cardiol       Date:  2018-07-10       Impact factor: 5.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.